StockMarketWire.com – Verona Pharma said the first patient in a clinical trial to further evaluate the efficacy of VRP700 as a novel treatment for chronic severe cough has been dosed with the drug. It was anticipated that data from this clinical trial will be available in the first half of 2014.
In this randomised, double-blind, placebo-controlled crossover study, a total of 20 adults with idiopathic pulmonary fibrosis (IPF) will be treated, by inhalation, with a single nebulized dose of VRP700.
Read the entire article at:
For more information about Idiopathic Pulmonary Fibrosis please visit our website www.ipftoday.com and don’t forget to like us on www.facebook.com/IPFToday
